KDR and neoplasm: Sorafenib, a multikinase inhibitor, suppresses tumor growth and angiogenesis by targeting RAF kinases (inhibiting RAF/MEK/ERK signaling activation) and receptor tyrosine kinases (e.g., VEGFR, PDGFR).